Co-registering current and prior scans to automatically detect, map, and quantify lesion change over time
Longitudinal comparison begins before any pixel is analyzed: the system must first locate the correct prior imaging study from the picture archiving and communication system (PACS). Matching is done on modality, body region, contrast protocol, and acquisition parameters, since comparing scans acquired under different technical conditions can introduce spurious apparent change.
Cancer treatment decisions hinge on whether a tumor is shrinking, stable, or growing between visits. Response Evaluation Criteria in Solid Tumors (RECIST 1.1) formalizes this: target lesions are measured along their longest diameter, and a ≥30% decrease from baseline defines a Partial Response, a ≥20% increase (and ≥5 mm absolute) from the smallest recorded sum defines Progressive Disease, and everything between is Stable Disease. Immunotherapy trials increasingly use iRECIST, which tolerates an initial apparent increase in tumor burden (pseudoprogression) before confirming true progression on a follow-up scan.
Because these thresholds are simple percentage cutoffs applied to error-prone manual measurements, small differences in how a lesion is measured can flip a patient between response categories. A retrieval-and-comparison pipeline that consistently pulls the correct prior study is the first safeguard against measurement drift — comparing against the wrong baseline (or a technically mismatched one) undermines every downstream calculation.
Under RECIST 1.1, the difference between "partial response" and "stable disease" can hinge on a few millimeters of measured diameter — well within the ±20–30% inter-reader variability reported for manual caliper measurements on irregular lesions.
Retrieval systems query the PACS/VNA using DICOM metadata — patient ID, modality, body part examined, series description, and acquisition date — to shortlist candidate prior studies. A ranking model then scores candidates by protocol similarity: same modality (CT vs. MRI), comparable slice thickness and reconstruction kernel, matching contrast phase, and coil/scanner consistency for MRI.
When multiple priors exist, the system typically favors the most recent directly comparable study, but oncology trend reporting also retains the baseline (pre-treatment) study as a fixed reference point, since RECIST nadir and progression calculations are anchored to both the baseline and the smallest interval measurement recorded at any point during treatment, not just the immediately preceding visit.
Radiologists have always performed this retrieval step manually, scrolling through a patient's imaging history to find a comparable prior exam — a process that can take several minutes per case, particularly for patients with a long imaging history. Automated retrieval and pre-loading of the correct comparator study measurably shortens interpretation time and reduces the chance that a suboptimal or technically mismatched prior is used for comparison, which is itself a recognized source of measurement error in serial imaging.
A new scan is acquired at the current visit. To make automated change detection reliable, the acquisition protocol — slice thickness, field of view, contrast timing, and where possible the scanner itself — is matched as closely as practical to the prior study, since protocol drift between visits is one of the largest confounders in longitudinal imaging analysis.
Voxel-wise change detection assumes that any measured difference reflects true anatomical change, not a difference in how the two scans were acquired. Differences in slice thickness, reconstruction kernel, contrast bolus timing, or patient positioning can each introduce apparent intensity or size changes that have nothing to do with disease. Departmental protocols for oncology follow-up imaging therefore specify a fixed acquisition recipe intended to be reused at every subsequent visit for that patient.
When exact protocol matching is not possible — a patient switches institutions, or scanner hardware is upgraded — the co-registration and normalization steps in the next stage must work harder to compensate, and residual uncertainty is typically flagged in the report rather than silently absorbed into the change estimate.
Before a new study is handed to the comparison pipeline, automated QC checks confirm sufficient image quality: absence of severe motion artifact, adequate contrast enhancement, and full anatomical coverage of the region containing the target lesion(s). A scan that fails QC is flagged for repeat or manual review rather than being silently compared, since a low-quality current study can otherwise masquerade as a genuine interval change.
A single course of imaging protocol drift — for example a 2–3 mm change in reconstructed slice thickness — can shift a measured lesion volume by a magnitude comparable to several months of true tumor growth, which is why protocol matching is treated as a first-class requirement rather than a convenience.
The same acquisition-matching discipline applies wherever a disease process is tracked over months to years: multiple sclerosis surveillance MRI is typically repeated on comparable sequences (3D FLAIR, post-contrast T1) roughly annually to detect new or enlarging demyelinating lesions per the McDonald criteria, and neurodegenerative disease monitoring (e.g., serial volumetric MRI in Alzheimer's trials) depends on matched T1-weighted acquisitions to reliably measure hippocampal and whole-brain atrophy rates on the order of 1–2% per year — changes far too small to detect reliably without consistent protocols.
Prior and current volumes are spatially aligned using deformable (non-rigid) registration to correct for differences in patient positioning, breathing phase, bladder or bowel filling, and minor anatomical shifts between imaging sessions — a necessary step before any voxel can be meaningfully compared across the two timepoints.
Rigid registration alone — translating and rotating one volume to match the other — cannot correct for the non-uniform deformation that occurs between two separate scanning sessions: organs shift with breathing phase, soft tissue compresses differently under table pressure, and the bowel or bladder fills to a different degree. Deformable registration instead estimates a dense displacement field, mapping every voxel in the current volume to its corresponding anatomical location in the prior volume.
Common approaches include B-spline free-form deformation and diffeomorphic algorithms (e.g., SyN/ANTs, or learned deep-learning registration networks) that optimize a similarity metric — mutual information or normalized cross-correlation — while regularizing the deformation field to remain smooth and anatomically plausible (avoiding folding or tearing). The result is a non-linear warp that brings corresponding anatomical structures into voxel-level alignment, at which point subtraction between the two volumes becomes meaningful.
Modern deep-learning-based deformable registration pipelines routinely achieve target registration errors under 2 mm across serial CT and MRI pairs — accurate enough to resolve the same order of change that clinically matters for RECIST-scale tumor measurements.
A subtlety of longitudinal registration is that the target lesion is, by definition, one of the structures most likely to have changed shape between scans — yet the algorithm must not force it into perfect alignment, or genuine growth would be erased before it can be measured. Most pipelines therefore register on the surrounding stable anatomy (bony landmarks, vasculature, organ boundaries) while treating the lesion region itself as a "masked" area during optimization, so the deformation field carries the correct context up to the lesion boundary without artificially deforming the lesion to match.
Traditional workflow has radiologists mentally register two scans by eye, scrolling back and forth between prior and current series — a cognitively demanding task especially for subtle or irregularly shaped lesions. Studies comparing automated deformable-registration-assisted reading against unaided side-by-side comparison have found meaningful reductions in reading time and improved consistency in detecting small interval changes, particularly for multifocal or diffuse disease where dozens of lesions must be tracked simultaneously.
Once prior and current volumes are co-registered, a voxel-by-voxel subtraction or intensity comparison generates a change map: regions where the current scan shows more tissue/enhancement than the prior are flagged as growth, regions showing less are flagged as shrinkage, and newly appearing foci are flagged as new findings — all overlaid directly on the anatomy for the reader.
With voxel correspondence established, the algorithm computes a difference signal at every location — for CT this may be a Hounsfield unit subtraction or a segmented-volume difference; for contrast-enhanced MRI it may be signal-intensity change within the enhancing lesion mask. The result is thresholded and color-coded: warm colors (red/orange) mark voxels where the current study shows increased size or enhancement relative to prior, cool colors (blue) mark voxels where it has decreased, and a distinct marker highlights entirely new foci with no prior counterpart.
Because raw subtraction is sensitive to residual noise and any imperfect registration, most pipelines apply morphological filtering and a minimum-cluster-size threshold so that isolated single-voxel differences (registration noise) are suppressed while genuine, spatially coherent regions of change are retained and reported.
RECIST's reliance on a single longest-diameter measurement is a deliberate simplification chosen for reproducibility across thousands of trial sites — but it is a coarse proxy for true tumor burden, especially for irregularly shaped or lobulated lesions where the same lesion can be measured differently by different readers, or even by the same reader on different days. Automated voxel-wise volumetric analysis captures the full three-dimensional extent of change and is far less sensitive to the specific slice or axis a human reader happens to choose for the caliper measurement.
This matters most for borderline cases sitting near a RECIST threshold: a lesion measured as growing 18% by one reader and 22% by another (crossing the progression threshold) illustrates exactly the kind of ambiguity that voxel-level volumetric quantification is designed to reduce.
Reported inter-observer variability for manual RECIST diameter measurements on irregular lesions can exceed 20–30%, enough on its own to flip a borderline case across the ±20%/30% RECIST response-category thresholds — a gap automated volumetric change detection is specifically designed to close.
Voxel-wise change mapping generalizes directly to non-oncologic longitudinal tracking. In multiple sclerosis, automated subtraction of serial FLAIR volumes highlights new or enlarging demyelinating lesions that satisfy McDonald criteria for dissemination in time, work that is otherwise labor-intensive to perform lesion-by-lesion by eye. In neurodegenerative disease, voxel-based morphometry and boundary-shift-integral techniques applied to serial structural MRI quantify regional brain atrophy rates as small as 1–2% per year, supporting both clinical monitoring and use as an imaging biomarker in Alzheimer's and other dementia trials.
Lesion size and volume changes are quantified numerically and assembled into a longitudinal trend report: a running record of measurements across every prior timepoint, the computed growth or response rate, and an automatically suggested RECIST/iRECIST category — handed to the radiologist and oncologist as a structured summary rather than a stack of separate reports to reconcile by hand.
Rather than treating each visit as an isolated comparison to only the immediately preceding scan, the trend report plots measured lesion size (or volume) at every available timepoint, anchored to both the treatment baseline and the RECIST nadir (smallest recorded measurement). This running curve makes the trajectory of disease immediately visible — a steady linear decline under a therapy, a plateau suggesting stable disease, or an inflection point where growth resumes and treatment may need to change — in a way that a single side-by-side comparison of two scans cannot convey.
Growth rate is typically expressed both as a percentage change over the interval and as an absolute rate (e.g., mm/month or cm³/month), since the clinical significance of a given percentage change depends heavily on how much time has elapsed between scans — a 10% increase over one month is a very different signal than the same 10% increase over a year.
Automated longitudinal reporting tools are validated by comparing their computed RECIST/iRECIST category against expert manual adjudication on the same case series, with concordance and time-savings both reported. Because the automated measurement is deterministic and reproducible — the same input volumes always yield the same measurement — it also removes a source of variability across serial reads by potentially different radiologists over the course of a long treatment history, which is itself a meaningful source of noise in real-world trend data.
Critically, these systems are deployed as decision support rather than autonomous diagnosis: the change map, trend curve, and suggested category are presented for radiologist review and sign-off, with the human reader retaining responsibility for confirming that apparent change reflects true disease progression rather than an artifact of positioning, contrast timing, or an incidental unrelated finding.
A 2024-era automated longitudinal reporting workflow can take a radiologist from raw prior-and-current volumes to a reviewed, quantified trend report in well under the time it would take to manually re-measure and tabulate even a handful of target lesions by hand — compounding across a patient's full multi-year imaging history.
The same trend-quantification model extends naturally to any chronic, slowly evolving condition tracked with serial imaging: annual brain MRI trend curves of hippocampal or whole-brain volume support monitoring of neurodegenerative disease progression, and cumulative new-lesion counts across yearly MRI form the backbone of disease-activity monitoring in multiple sclerosis, where a rising lesion trend line can prompt a change in disease-modifying therapy well before a patient reports new symptoms.